Drug safety check: how did COVID-19 treatment perform in real patients?
NCT ID NCT05687877
Summary
This study monitored the safety of Evusheld, a drug used to treat and prevent COVID-19 symptoms, after it was approved for use in Japan. It followed 366 Japanese patients who received the drug in real-world medical settings to track any side effects. The goal was to understand the drug's safety profile in everyday practice, particularly for people at high risk of severe COVID-19 or those who cannot get vaccinated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS COV 2 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aichi, Japan
-
Research Site
Chiba, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Fukushima, Japan
-
Research Site
Hiroshima, Japan
-
Research Site
Hokkaido, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Ibaraki, Japan
-
Research Site
Ishikawa, Japan
-
Research Site
Kagoshima, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Mie, Japan
-
Research Site
Nara, Japan
-
Research Site
Numakunai, Japan
-
Research Site
Osaka, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Tottori, Japan
Conditions
Explore the condition pages connected to this study.